EP0655924A4 - COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION. - Google Patents

COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.

Info

Publication number
EP0655924A4
EP0655924A4 EP93906955A EP93906955A EP0655924A4 EP 0655924 A4 EP0655924 A4 EP 0655924A4 EP 93906955 A EP93906955 A EP 93906955A EP 93906955 A EP93906955 A EP 93906955A EP 0655924 A4 EP0655924 A4 EP 0655924A4
Authority
EP
European Patent Office
Prior art keywords
erbb
combination
monoclonal antibodies
monoclonal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93906955A
Other languages
German (de)
English (en)
Other versions
EP0655924A1 (fr
Inventor
Philip G Kasprzyk
Charles R King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncologix Inc
Original Assignee
Oncologix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncologix Inc filed Critical Oncologix Inc
Publication of EP0655924A1 publication Critical patent/EP0655924A1/fr
Publication of EP0655924A4 publication Critical patent/EP0655924A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP93906955A 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION. Withdrawn EP0655924A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90655592A 1992-06-30 1992-06-30
US906555 1992-06-30
PCT/US1992/008545 WO1994000136A1 (fr) 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION

Publications (2)

Publication Number Publication Date
EP0655924A1 EP0655924A1 (fr) 1995-06-07
EP0655924A4 true EP0655924A4 (fr) 1996-09-11

Family

ID=25422648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93906955A Withdrawn EP0655924A4 (fr) 1992-06-30 1992-10-21 COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.

Country Status (6)

Country Link
EP (1) EP0655924A4 (fr)
JP (1) JPH08504172A (fr)
KR (1) KR100269879B1 (fr)
AU (1) AU687346B2 (fr)
CA (1) CA2120745A1 (fr)
WO (1) WO1994000136A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733752B1 (en) 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US5759776A (en) * 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1947119A3 (fr) 1997-12-12 2012-12-19 Genentech, Inc. Traitement du cancer avec un anticorps Anti-ERBB2 combiné à une chimiothérapie
EP1941905A1 (fr) 1998-03-27 2008-07-09 Genentech, Inc. Synergie d'anticorps APO-2 ligand-anti-her-2
CA2704600C (fr) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. Methode de production d'anticorps avec activite adcc accrue
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
WO2001076630A1 (fr) * 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et remedes contre la polyarthrite rhumatoide
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
CA2407556C (fr) 2000-05-19 2011-06-21 Genentech, Inc. Analyse de detection genique permettant d'ameliorer la probabilite d'une reponse efficace a une therapie du cancer basee sur un antagoniste d'erbb
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2289942B1 (fr) 2002-04-10 2013-07-31 Genentech, Inc. Variantes d'anticorps anti-HER2
WO2004008099A2 (fr) 2002-07-15 2004-01-22 Genentech, Inc. Procedes d'identification de tumeurs sensibles a un traitement par anticorps anti-erbb2
CN100408097C (zh) * 2002-10-10 2008-08-06 默克专利有限公司 双特异性抗erb-b抗体及其在肿瘤治疗中的用途
WO2004032961A1 (fr) * 2002-10-10 2004-04-22 Merck Patent Gmbh Anticorps bispecifiques contre erb utilises en therapie antitumorale
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2478912B1 (fr) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Conjugués d'auristatin avec des anticorps dirigés contre le HER2 ou le CD22 et leur usage thérapeutique
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (fr) 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
US8350011B2 (en) 2006-08-04 2013-01-08 Medimmune Limited Antibodies to ErbB2
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010022736A2 (fr) 2008-08-29 2010-03-04 Symphogen A/S Compositions de l'anticorps de recombinaison anti-récepteur du facteur de croissance anti-épidermique egfr
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011130580A1 (fr) 2010-04-15 2011-10-20 Alper Biotech, Llc Anticorps monoclonaux contre antigènes her2 et leurs utilisations
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2751285B2 (fr) 2011-08-31 2020-04-01 Genentech, Inc. Procédé d'analyse de la sensibilité d'une tumeur à des inhibiteurs de la egfr kinase
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US11058768B2 (en) 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
EP3303373B1 (fr) 2015-05-30 2020-04-08 Molecular Templates, Inc. Supports de sous-unité a de toxine de shiga, déimmunisés, et molécules de ciblage de cellule les comprenant
CN107787331B (zh) 2015-06-17 2022-01-11 豪夫迈·罗氏有限公司 抗her2抗体和使用方法
EP3567049A4 (fr) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
EP3560945A1 (fr) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Procédés de purification de polypeptides utilisant des polysorbates
WO2020035577A1 (fr) 2018-08-16 2020-02-20 Cantargia Ab Compositions d'anticorps anti-il1rap
WO2023044483A2 (fr) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer positif her2
GB202309703D0 (en) 2023-06-27 2023-08-09 Epsilogen Ltd Composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (fr) * 1988-02-26 1989-09-06 Neorx Corporation Anticorps fonctionnellement spécifiques
WO1991005264A1 (fr) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection et quantification des proteines apparentees neu dans les liquides biologiques des humains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331034A2 (fr) * 1988-02-26 1989-09-06 Neorx Corporation Anticorps fonctionnellement spécifiques
WO1991005264A1 (fr) * 1989-09-29 1991-04-18 Oncogenetics Partners Detection et quantification des proteines apparentees neu dans les liquides biologiques des humains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KASPRZYK ET AL: "THERAPY OF AN ANIMAL MODEL OF HUMAN GASTRIC CANCER USING A COMBINATION OF ANTI-ERBB-2 MONOCLONAL ANTIBODIES", CANCER RESEARCH, vol. 52, 15 May 1992 (1992-05-15), pages 2771 - 2776, XP002014292 *
See also references of WO9400136A1 *

Also Published As

Publication number Publication date
KR100269879B1 (ko) 2000-10-16
JPH08504172A (ja) 1996-05-07
WO1994000136A1 (fr) 1994-01-06
EP0655924A1 (fr) 1995-06-07
AU3773393A (en) 1994-01-24
CA2120745A1 (fr) 1994-01-06
AU687346B2 (en) 1998-02-26
KR950700075A (ko) 1995-01-16

Similar Documents

Publication Publication Date Title
EP0655924A4 (fr) COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.
HU9601574D0 (en) Humanized antibodies and uses thereof
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
AU4289496A (en) Method of promoting an immune response with a bispecific antibody
AU4618193A (en) Humanized antibodies
NZ230786A (en) A method of reducing the heterogeneity of secreted monoclonal antibodies
EP0578515A3 (fr) Anticorps monoclonaux humanisés.
ZA973664B (en) Hepatitis b monoclonal antibodies
GB9412166D0 (en) Retargetting antibodies
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
EP0506523A3 (en) Monoclonal antibodies
EP0909278A4 (fr) Immunoglobuline g liee a la nephropathie et anticorps contre celle-ci
EP0218587A4 (fr) Anticorps monoclonaux et procede d'immunisation les utilisant.
ZA89258B (en) Monoclonal antibodies
AU9143991A (en) Monoclonal antibody op-g2 and method of use
EP0582450A3 (fr) Anticorps contre récepteur de l'oxytocine et leur production.
EP0654532A4 (fr) Anticorps monoclonal antimucoglycoproteine.
GB8820036D0 (en) Monoclonal antibodies
EP0468056A4 (en) Anti-procollagenase monoclonal antibodies and a method for the assay of procollagenase utilizing thereof
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0520436A3 (en) Monoclonal antibody, method of production thereof and use thereof
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype
GB9212074D0 (en) Monoclonal antibody
SG64332A1 (en) Monoclonal antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: A61K 35/14

RHK1 Main classification (correction)

Ipc: C12N 15/13

A4 Supplementary search report drawn up and despatched

Effective date: 19960726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 20000712

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010123